Find publications by Adaptive as well as our collaborators and partners who leverage our technologies.




Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

Algazi et al.

  • Clinical Cancer Research
  • June 2020

Immunotherapy of CT26 Murine Tumors Is Characterized by an Oligoclonal Response of Tissue-Resident Memory T Cells Against the AH1 Rejection Antigen

Stringhini et al.

  • European Journal of Immunology
  • May 2020

Neoadjuvant Immunotherapy Leads to Pathological Responses in MMR-proficient and MMR-deficient Early-Stage Colon Cancers

Chalabi et al.

  • Nature Medicine
  • April 2020

Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas

Aslan et al.

  • Nature Communications
  • February 2020

Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R- Dependent STING Activation by Tumor-Derived cGAMP

Zhou et al.

  • Immunity
  • February 2020

T-cell lymphoma secondary to checkpoint inhibitor therapy

Anand et al.

  • Journal for ImmunoTherapy of Cancer
  • February 2020

Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy

Valpione et al.

  • Nature Cancer
  • February 2020

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Sharma et al.

  • Nature Communications
  • January 2020

Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy

Sheih et al.

  • Nature Communications
  • January 2020